Aegis Capital sees good things in Stemline Therapeutics' (STML +1.8%) future, noting that the...

|About: Stemline Therapeutics (STML)|By:, SA News Editor

Aegis Capital sees good things in Stemline Therapeutics' (STML +1.8%) future, noting that the company "appears to be exceptionally well-funded [and] should continue to attract interest based on the accelerated development pathway for its lead drug candidate, SL-401 " (I, II, III). The shares are reiterated at Buy and the price target is raised to $40 from $35.